Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma

International Journal of Hematology

Volumn 86, Issue 3, 2007, Pages 253-260

  Izaki, Sakurako ^a   Goto, Hiroaki ^a   Okuda, Kumiko ^a   Matsuda, Motoi ^a   Watanabe, Yuka ^a   Fujioka, Kenichirou ^a   Hanzawa, Noriyuki ^a   Sumita, Hiroko ^a   Takahashi, Hiroyuki ^a   Goto, Shoko ^a   Kai, Sumio ^a   Sekiguchi, Haruyuki ^a   Funabiki, Tetsunori ^a   Sasaki, Hideki ^a   Ikuta, Koichiro ^a   Yokota, Shumpei ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

ACNU; Busulfan; Children; Conditioning; Etoposide; L PAM

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; BUSULFAN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; ETOPOSIDE; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; NIMUSTINE; THYROTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CAUSE OF DEATH; CHILD; CHILDHOOD LEUKEMIA; CHRONIC GRAFT VERSUS HOST DISEASE; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; GROWTH RETARDATION; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; INCIDENCE; INTERSTITIAL PNEUMONIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LUNG TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; RETROSPECTIVE STUDY; SECOND CANCER; SEIZURE; SIDE EFFECT; STEM CELL TRANSPLANTATION; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; NIMUSTINE; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 36048971765     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06231     Document Type: Article

References (41)

1. Cohen A, Rovelli A, Bakker B, et al, on behalf of the EBMT Late-Effects Working Party. Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late-Effects-EBMT. Blood. 1999;93:4109-4115.
2. Cohen A, Rovelli R, Zecea S, et al. Endocrine late effects in children who underwent bone marrow transplantation: review. Bone Marrow Transplant. 1998;21(suppl 2):S64-S67.
3. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897-904.
4. Deeg HJ, Socié G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386-392.
5. Sanders JE, Buckner CD, Leonard JM, et al. Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation. Transplantation. 1983;36:252-255.
6. Blaise D, Maranchini D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxanlotal body irradiation as preparative regimen: a report from the Group d'Études de la Greffe de Möelle Osseuse. Blood. 1992;79:2578-2582.
7. Ringdén O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with lotal body irradiation as conditioning in allogeneic marrow transplantation recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood. 1994;83:2723-2730.
8. Davies SM, Ramsay NKC, Klein JP, et al. Comparison of preparative regimens in transplants for children with acule lymphoblastic leukemia. J Clin Oncol. 2000;18:340-347.
9. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant. 2003;32:543-548.
10. Shah AJ, Lenarsky C, Kapoor N, et al. Busulfan and cyclophosphamide as a conditioning regimen for pediatric acute lymphoblastic leukemia patients undergoing bone marrow transplantation. J Pediatr Hematol Oncol. 2004;26:91-97.
11. von Bueltzingsloewen A, Esperou-Bourdeau H, Souillet G, et al. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a cooperative study of the Société Française de Greffe de Moelle. Bone Marrow Transplant. 1995;16:521-527.
12. Cesaro S, Meloni G, Messina C, et al. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation. Bone Marrow Transplant. 2001;28:131-136.
13. Dai QY, Souillet G, Bertrand Y, et al. Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Bone Marrow Transplant. 2004;34:667-673.
14. Matsuyama T, Kojima S, Kato K. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen. Bone Marrow Transplant. 1998;22:21-26.
15. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562-1568.
16. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
17. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347-1353.
18. Socié G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001;98:3569-3574.
19. Granados E, de la Cämara R, Madero L, et al. Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long-term event-free survival with conditioning regimens containing total body irradiation. Haematologica. 2000;85:1060-1067.
20. Michel G, Gluckman E, Esperou-Bourdeau H, et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation: a report from the Société Française de Greffe de Moelle. J Clin Oncol. 1994;12:1217-1222.
21. Kroger N, Hoffknecht M, Hänel M, et al. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Bone Marrow Transplant. 1998;21:1171-1175.
22. Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood. 1993;81:311-318.
23. Chao NJ, Stein AS, Long GD, et al. Busulfan/etoposide: initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood. 1993;81:319-323.
24. Copelan EA, Penza SL, Pohlman B, et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2000;25:1243-1248.
25. Sandler ES, Hagg R, Coppes MJ, et al. Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium. Med Pediatr Oncol. 2000;35:403-409.
26. Horstmann M, Kroschke G, Stockshlader M, et al. Early toxicity of intensified conditioning with etoposide combined with total body irradiation/cyclophosphamide or busulfan/cyclophosphamide in children undergoing autologous or allogeneic bone marrow transplantation. Pediatr Hematol Oncol. 1996;13:45-53.
27. von Bueltzingsloewen A, Bélanger R, Perreault C, et al. Allogeneic bone marrow transplantation following busulfan-cyclophosphamide with or without etoposide conditioning regimen for patients with acute lymphoblastic leukaemia. Br J Haematol. 1993;85:706-713.
28. Philip T, Chauvin F, Armitage J, et al. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood. 1991;77:1587-1592.
29. Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: a single-center eight-year study of 155 patients. Blood. 1993;81:1137-1145.
30. Jagannath S, Dicke KA, Armitage JO, et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med. 1986;104:163-168.
31. Maraninchi D, Pico JL, Hartmann O, et al. High-dose melphalan with or without bone marrow transplantation: a study of dose-effect in patients with refractory and/or relapsed acute leukemia. Cancer Treat Rep. 1986;70:445-448.
32. Takaue Y, Watanabe T, Hoshi Y, et al. Effectiveness of high-dose MCNU therapy and hematopoietic stem cell allografts treatment of childhood acute leukemia/lymphoma with high-risk features. Cancer. 1991;67:1830-1837.
33. Wheeler C, Antin JH, Churchill WH, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol. 1990;8:648-656.
34. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31-42.
35. Ritchie DS, Szer J, Roberts AW, Shuttleworth R Grigg AP. A phase 1 dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;30:645-650.
36. Thompson DS, Hainsworth JD, Hande KR, Holzmer MC, Greco FA. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase 1/11 study. J Clin Oncol. 1993;11:1322-1328.
37. Ringdén O, Remberger M, Ruutu T, et al, for the Nordic Bone Marrow Transplantation Group. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long term results of a randomized trial in allogeneic marrow recipients with leukemia. Blood. 1999;93:2196-2201.
38. Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant. 1998;22:989-994.
39. Afify Z, Shaw PJ, Clavano-Harding A, Cowell CT. Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide. Bone Marrow Transplant. 2000;25:1087-1092.
40. Vaidya SJ, Atra A, Bahl S, et al. Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: long-term follow-up. Bone Marrow Transplant. 2000;25:599-603.
41. Boulad F, Bromley M, Black P, et al.Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation. Bone Marrow Transplant. 1995;15:71-76.